Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera

Strategic Collaboration:
Metsera, a clinical-stage biopharmaceutical company, and Amneal Pharmaceuticals, a global pharmaceutical company, have entered into a strategic collaboration to develop and supply a portfolio of next-generation medicines for obesity and metabolic diseases.

Manufacturing Partnership:
Amneal will serve as Metsera’s preferred supply partner for developed markets, including the United States and Europe, and will also have a license to commercialize Metsera’s products in select emerging markets.

Manufacturing Facilities:
Amneal plans to construct two new manufacturing facilities in India, one for peptide synthesis and one for sterile fill-finish operations, with a total net cost of $150 million to $200 million over the next four to five years.

Product Development:
Amneal will support Metsera with product development activities, including drug substance manufacturing, product formulation, and drug-device development.

Leadership Transition:
Clive Meanwell has handed over the CEO role at Metsera, with Whit Bernard now serving as the Chief Executive Officer.

Recent Developments:
Metsera recently unveiled positive early-stage data for its investigational long-acting GLP-1 injectable drug, MET-097, showing a 7.5% drop in body weight at 36 days, and plans to accelerate its development with a Phase IIb study.